BioSpace News Archive

Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the closing of an underwritten public offering of 5,566,000 shares of its common stock

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the closing of its initial public offering of 4,819,277 units

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an aggregate of 161,000 shares of Akebia’s common stock on January 29, 2021, as inducements material to each such employee’s entering into employment with Akebia.

- Ensysce Biosciences, a clinical stage biopharmaceutical company with a mission to solve prescription drug abuse, is focused on launching a new class of opioid pain therapeutics

Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock.

Ulbrich understands the need for rapid Medical Device development cycles. With the new Ulbrich Braid Wire Accelerator™ Program, timelines and specific design performance characteristics are faster and more precise than ever before.

BioKansas announces their new strategic plan for 2021-2025 that focuses on five transformative goals. The new strategic plan aims to have substantial impacts on the bioscience industry and broader economy in Kansas through building a sustainable nationally competitive bioscience enterprise with a strong diverse workforce.

Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.

Investment will bring Canada’s first centre of manufacturing excellence of nanomedicine-based RNA vaccines, gene therapies and cell therapies. At project completion early in 2023, the approximately 40,000 square foot leased bio-manufacturing facility will have multiple GMP suites with manufacturing lines for the end-to-end manufacturing of genetic medicines.